The numbers may be too small to allow any firm conclusions to be drawn, but Clavis Pharma ASA reported positive Phase II data for a combination of elacytarabine and idarubicin in patients with early stage acute myeloid leukemia (AML) who had either relapsed on or proved refractory to a first-line therapy that included cytarabine.